A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Julia Glade Bender1, Susan M. Blaney2, Scott Borinstein3, Joel M. Reid4, Sylvain Baruchel5, Charlotte Ahern2, Ashish M. Ingle6, Darrell J. Yamashiro1, Alice Chen7, Brenda Weigel8, Peter C. Adamson9, and Julie R. Park10

Abstract

**Purpose:** Aflibercept is a novel decoy receptor that efficiently neutralizes circulating VEGF. A pediatric phase I trial was conducted to define the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of aflibercept.

**Experimental Design:** Cohorts of three to six children with refractory solid tumors received aflibercept intravenously over 60 minutes every 14 days, at 2.0, 2.5, or 3.0 mg/kg/dose. PK sampling and analysis of peripheral blood biomarkers were conducted with the initial dose.

**Results:** Twenty-one eligible patients were enrolled; 18 were fully evaluable for toxicity. One of six patients receiving 2.0 mg/kg/dose developed dose-limiting intratumoral hemorrhage and two of six receiving 3.0 mg/kg/dose developed either dose-limiting tumor pain or tissue necrosis. None of the six patients receiving 2.5 mg/kg/dose developed DLTs, defining this as the MTD. The most common non-DLTs were hypertension and fatigue. Three patients with hepatocellular carcinoma, hepatoblastoma and clear cell sarcoma had stable disease for >13 weeks. At the MTD, the ratio of free-to-bound aflibercept serum concentration was 2.10 on day 8 but only 0.44 by day 15. A rapid decrease in VEGF (P < 0.05) and increase in placental growth factor (PIGF; P < 0.05) from baseline was observed in response to aflibercept by day 2.

**Conclusions:** The aflibercept MTD in children of 2.5 mg/kg/dose every 14 days is lower than the adult recommended dose of 4.0 mg/kg. This dose achieves, but does not sustain, free aflibercept concentrations in excess of bound. Tumor pain and hemorrhage may be evidence of antitumor activity but were dose-limiting.

Clin Cancer Res; 18(18); 5081–9. ©2012 AACR.

Introduction

Extensive tumor vascularity has been linked to advanced stage and poor prognosis in both adult and pediatric malignancy. VEGF delivers a powerful mitogenic and survival stimulus to tumor vessel endothelium and enhances vascular permeability, promoting both cancer growth and metastasis (1). To date, several drugs targeting VEGF have been shown to benefit adult patients with cancer (2). Aflibercept (VEGF Trap; Regeneron Pharmaceuticals, and Sanofi-Aventis Oncology) is a fully human, composite decoy receptor, in which the extracellular domains of VEGF receptors-1 and -2 (VEGFR-1 and VEGFR-2) are fused to an Fc segment of IgG1. Aflibercept sequesters VEGF, VEGF-B, and placental growth factor (PIGF) with extraordinarily high affinity (VEGF165, Kd = 1 pmol/L; ref. 3). Aflibercept caused striking inhibition of tumor angiogenesis, resulting in regression of established tumors, in orthotopic xenografts derived from a pediatric renal cancer harboring the EWS/FLI translocation as well as from a hepatoblastoma (4, 5). In neuroblastoma models, aflibercept substantially decreased co-opted vessels (6).

The adult recommended phase II dose of aflibercept administered as a single agent is 4.0 mg/kg intravenously every 2 weeks, based on toxicity, pharmacokinetic (PK) profile, biomarker analysis, and antitumor activity. Proteinuria and rectal ulceration, occurring at 7.0 mg/kg, were the dose-limiting toxicities (DLT) in adults with refractory solid tumors (7). Common adverse events associated with aflibercept administration included fatigue (63.8%), dysphonia (46.8%), hypertension (38.3%), nausea (36.2%), vomiting (27.7), and proteinuria (10.6%). Objective tumor...
Translational Relevance

Aflibercept is novel decoy receptor, which potently binds VEGF, causing striking inhibition of angiogenesis and tumor regression in pediatric preclinical models. We conducted a phase I and pharmacokinetic study of aflibercept in children with refractory cancer to determine the maximum tolerated dose (MTD). Despite similar pharmacokinetic parameters, children tolerated lower doses of aflibercept than adults, due to dose-limiting tumor pain, necrosis, and hemorrhage. Possible explanations for increased tumor-related toxicity include tumorbulk, tumor histology, and the relative contribution of VEGF to pediatric tumor growth. At the MTD, children achieved, but did not sustain, free in excess of bound aflibercept. Nonetheless, presumed effects on tumor vasculature and modulation of plasma biomarkers imply biologic activity. The results of this trial suggest that both tumor and host factors may determine susceptibility to aflibercept and highlight the need to identify biomarkers able to predict which patients will benefit from anti-VEGF therapy.

responses were observed at doses of 3.0 mg/kg and higher. At doses levels of 2.0 mg/kg and higher, free aflibercept concentrations increased proportionally with dose, but bound aflibercept concentrations appeared to plateau, indicating maximal ligand sequestration had been achieved. Recently, the addition of aflibercept has been shown to increase overall survival in patients receiving second-line irinotecan/5-fluorouracil (5-FU; FOLFIRI) chemotherapy for metastatic colorectal cancer (8), and a substantial tumor regression in pediatric preclinical models. We bind VEGF to pediatric tumor growth. At the MTD, patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer (9).

Between May 2008 and October 2009, the phase I consortium of the Children’s Oncology Group conducted a trial in pediatric patients with refractory solid tumors. Primary aims included estimating the maximum tolerated dose (MTD) of aflibercept administered intravenously as monotherapy every 14 days, describing dose-limiting and other toxicities, and evaluating the ability to achieve and sustain free in excess of bound aflibercept levels over the duration of the dosing interval.

Materials and Methods

Study participants

Patients 1 to 21 years of age with solid or central nervous system (CNS) malignancy and measurable or evaluable disease and for whom no curative therapy existed were eligible. Following episodes of dose-limiting intratumoral hemorrhage and tumor rupture in 2 of the initial 14 patients, patients with primary or metastatic CNS tumors and/or pleural-based lesions were excluded from subsequent enrollment (Amendment 4, April 2009). Patients were required to have a Karnofsky (age > 16 years) or Lansky (age ≤ 16 years) performance score ≥ 50 and to have recovered from prior therapy. Patients were also required to have adequate baseline renal, hepatic, and hematologic function, as well as a blood pressure within the 95th percentile for age, height, and gender (10) and not be receiving antihypertensive medication. Exclusion criteria included patients with clinically significant cardiovascular disease (e.g., pulmonary embolism, deep vein thrombosis, or other thromboembolic event within past 6 months); prior bleeding event, current bleeding diathesis, or treatment with anti-platelet or anti-thrombotic agents; recent or planned major surgery, evidence of chronically impaired wound healing, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment; pregnancy or lactation; uncontrolled infection; and concurrent use of other investigational or anticancer agents.

The Institutional Review Board of each participating site approved this trial. Written informed consent was obtained from all patients, including assent from minor subjects according to institutional guidelines.

Drug administration and study design

Aflibercept was supplied by Sanofi-Aventis Pharmaceuticals and distributed by the Cancer Therapy Evaluation Program (NCI, Bethesda, MD) in 100 mg (4 mL) or 200 mg (8 mL) vials to be further diluted in 0.9% sodium chloride or 5% dextrose to a final concentration between 0.6 and 8 mg/mL. Aflibercept was administered intravenously over 60 minutes every 2 weeks (1 cycle). Cycles could be repeated every 14 days for up to 24 months in patients without disease progression or DLTs. For the purposes of data reporting, one course encompassed 2 cycles.

The starting dose was 2.0 mg/kg/dose, the lowest dose at which complete VEGF ligand sequestration could be achieved in adults. Planned dose-escalations were to occur in increments of 1.0 mg/kg/dose. No intrapatient dose-escalation was allowed. A conventional 3 by 3, phase I dose-escalation scheme was used wherein the MTD was exceeded if either 2 of 3 or 2 of 6 subjects encountered DLTs. When this occurred at the second dose level (3.0 mg/kg), the study plan was modified to investigate an intermediate dose of 2.5 mg/kg (Amendment 4).

Toxicity assessment and disease evaluations

Toxicity monitoring included physical examination with blood pressure measurement, complete blood counts, and serum chemistries, including electrolytes, creatinine, alanine aminotransferase (ALT), bilirubin, total protein, and albumin (weekly during cycles 1 and 2, then before each cycle). Prothrombin time and activated partial thromboplastin time (PTT) were also evaluated once before each cycle. Clinical and laboratory adverse events were graded according to the NCI Common Terminology Criteria for Adverse Events version 3 (11). Gender and height-adjusted norms were used to assess blood pressure elevation above the 95th percentile for age (10). The study used a previously described algorithm for the determination and
management of drug-related hypertension (12). Tibial radiographs were conducted in patients who had not yet achieved adult height. Response was evaluated using either Response Criteria in Solid Tumors (RECIST) or 2-dimen-
sional measurement for CNS tumors with imaging at base-
line, the end of cycle 2, and then every 4 cycles.

Definition of DLT and MTD
Hematologic DLT was defined as grade IV neutropenia or
grade IV thrombocytopenia of >7 days duration; grade III or
IV thrombocytopenia that required transfusion therapy
more than twice during a cycle; or myelosuppression that
caus ed delay of ≥14 days between cycles. Nonhematologic
DLTs included any grade IV toxicity; any grade III toxicity
with exceptions of nausea and vomiting of <3 days dura-
tion, ALT or aspartate aminotransferase (AST) elevations
that recovered to grade ≤1 by the time of the next cycle, fever
or infection <5 days, electrolyte abnormalities responsive
to oral supplementation and grade III pain adequately
controlled with narcotic analgesics; grade II proteinuria
(>2 g/24 h) not resolving to eligibility range within 4 weeks,
and medically significant grade II toxicity that persisted for
≥7 days and required treatment interruption. Dose-limiting
hypertension was specifically defined as any grade IV
hypertension, confirmed systolic or diastolic blood pressure
>25 mm Hg above the upper limit of normal, or an elevated
blood pressure not controlled by antihypertensive medica-
tion within 14 days (12). Patients with DLTs that resolved
within 7 days and continued to meet eligibility parameters
were eligible for one dose reduction. Aflibercept was per-
manently discontinued for recurrent DLTs, grade II arterial
thromboembolic events, any requirement for systemic
anticoagulation, thrombotic microangiopathy, bleeding
requiring acute medical management, transfusion or hos-
pitalization, reversible posterior leukoencephalopathy,
intestinal perforation, and fistula formation regardless of
anatomic location.

Only DLTs during course 1 (cycles 1 and 2) were con-
cidered for dose-escalation and determination of the MTD.
Patients were considered fully evaluable for toxicity if they
either developed a DLT or received at least 85% of the
prescribed dose over this interval. Patients not meeting
these criteria were replaced. The MTD was defined as the
dose level immediately below the dose level at which fewer
than one third of patients experienced a DLT.

Pharmacokinetics and pharmacodynamics
Mandatory plasma aflibercept levels were measured
before drug administration on days 1 and 8 (range, 7–9)
of cycle 1, and before day 1 of cycles 2, and 5, to assess ability
to achieve and maintain a target therapeutic dose, defined as
free in excess of bound aflibercept. Optional PK sampling
was obtained at 1 and 24 hours and 3 to 5 days after infusion
in cycle 1. Blood was collected from a site distant from the
infusion (if <6 days) into a Hemogard, 4.5-mL tube contain-
ing citrate buffer, theophylline adenosine, and dipyrida-
mole (B-D Cat #367947) to prevent platelet lysis during
plasma sample preparation. Samples were centrifuged at
approximately 1,200 × g for 15 minutes at room temper-
ature within 1 hour and the plasma stored frozen at ~20°C.
Free aflibercept concentration in plasma was measured
using ELISA with microplates coated with human VEGF,
whereas bound VEGF:aflibercept complex concentration
was measured using plates coated with anti-VEGF antibody.
Serum samples at baseline and before infusion every 8 weeks
were also obtained to measure anti-aflibercept antibody
testing by ELISA (Regeneron Pharmaceuticals, Inc).

Aflibercept plasma concentration–time data were fit by
standard noncompartmental methods using WINNONLIN
Pro version 4.1 (Pharsight). The terminal elimination rate
constant was determined by least-squares regression of the
serum concentration–time data for the last 2 to 3 time
points.

Voluntary pharmacodynamics (PD) samples for plasma
and cellular markers of angiogenesis were collected in EDTA
tubes, before the dose on day 1 and on day 2 of cycle 1 and
just before cycle 2. Plasma was immediately separated by
centrifugation at 4°C. Plasma angiogenic cytokines [VEGF,
soluble VEGFR-1 (sVEGFR-1) and soluble VEGFR-2
(sVEGFR-2), and PIGF] were conducted using commercially
available ELISA kits. Blood for total, progenitor, and apo-
potic circulating endothelial cells was shipped on ice to a
central laboratory and analyzed within 24 hours of collect-
ion according to previously described 4-color flow cyto-
metric methods (13, 14). Changes in biomarkers of angi-
genesis obtained at baseline, day 2, and at the end of cycle 1
were assessed using the paired t-test for normally distributed
data and the Wilcoxon signed-rank test for non-normal
data.

Results
Patient characteristics
Of the 22 patients enrolled at 14 centers, one patient was
deemed ineligible before start of therapy, as only 13 days
had passed since completion of radiation therapy. Char-
acteristics of the remaining 21 subjects are shown in Table 1.
Three patients were removed from therapy after cycle 1 and
therefore not evaluable for DLT (2 early disease progression;
1 ventriculoperitoneal shunt obstruction requiring surgical
revision). Six patients had received prior therapy with at
least one other VEGF blocking agent including one or more
of bevacizumab, sorafenib, sunitinib, or cediranib.

Dose-escalation and toxicity
Table 2 summarizes the number of patients experiencing
DLT by dose level. One of the first 3 evaluable patients at the
2.0 mg/kg dose level presented with abdominal pain and a
decrease in hemoglobin of 1.5 g/dL, 1 week following the
initial dose. This patient had a large heterogeneous primary
adenocortical carcinoma and was assessed as having
tumor-related grade III hemorrhage associated with pro-
gression by computed tomographic (CT) scan. An addition-
al 3 patients were entered at 2.0 mg/kg without incident.
At the 3.0 mg/kg dose level, a patient with synovial
sarcoma of the jaw, previously irradiated and with prior
the patient was removed from protocol for progressive disease. Three additional evaluable patients were entered at 3.0 mg/kg. One patient with epithelioid sarcoma and prior exposure to sorafenib developed grade III tumor-related subcutaneous tissue necrosis and absent formation at a groin site within 14 days of starting therapy and was removed from protocol therapy for delayed wound healing. Because 2 of 6 evaluable patients had DLTs, it was determined that the MTD had been exceeded at 3.0 mg/kg.

Interim PK data from patients who received 2.0 mg/kg/d showed the ability to achieve free aflibercept levels in excess of bound aflibercept levels at day 8 but inability to sustain these levels throughout the 14-day dosing interval (Table 5). The study was, therefore, amended to evaluate an intermediate dose of 2.5 mg/kg. There were no DLTs among the 6 patients entered and an MTD for pediatric patients was established as 2.5 mg/kg.

Non-DLTs at least possibly attributable to aflibercept and present in at least 10% of patients more than 37 courses are summarized in Table 3. The most frequent were hypertension, mild myelosuppression, fatigue, proteinuria, and dysphonia. Of the 9 patients who developed hypertension (43%), 6 patients (29%) required medication to control blood pressure. The median time to onset of first blood pressure elevation was 14 (range, 3–24) days and to initiation of single-agent antihypertensive therapy 18.5 (range, 3–32) days. No bony abnormalities were reported in 2 patients with open epiphyses who underwent serial plain radiographs.

### Pharmacokinetics, pharmacodynamics, and immunogenicity

Complete pharmacokinetic profiles for free aflibercept are available for 8 subjects (Fig. 1, upper blue curves). No meaningful difference in $C_{\text{max}}$ and area under the curve (AUC) could be detected between doses of 2 and 2.5 mg/kg in this limited sample; however, at 3 mg/kg, the mean (range) $C_{\text{max}}$ of 48.2 (32.9–58.7) μg/mL was approximately double that observed at the lower 2 doses and exposure also appeared to increase. The mean half-life, clearance, and volume of distribution at steady state ($V_{ss}$) values of free aflibercept were 4.5 days, 18.4 mL/kg/d, and 101 mL/kg, respectively (Table 4). Within the narrow dose range studied, clearance did not appear to be affected by dose.

Mid cycle (day 8) and trough (pre cycles 2 and 5) free and bound aflibercept concentrations were available for the majority of participants (Table 5). Bound VEGF:aflibercept complex concentrations were similar across dose levels at day 8 (2.3 ± 0.6 μg/mL) and the end of cycle 1 (3.4 ± 1.0 μg/mL), but the higher value at the end of cycle 1 indicated that a steady-state level of bound aflibercept was not reached before the end of cycle 1 (Fig. 1, lower red curves). Bound VEGF:aflibercept complex concentration continued to increase in the few patients sampled before cycle 5, suggesting that steady-state levels of bound aflibercept were not achieved because of a compensatory increase in ligand production. While free aflibercept exceeded bound aflibercept on day 8 for all dose levels studied, this was not

### Table 1. Patient characteristics for eligible patients ($N = 21$)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>12.9 (1.9–21.6)</td>
</tr>
<tr>
<td>Sex</td>
<td>11:10</td>
</tr>
<tr>
<td>Prior chemotherapy regimens</td>
<td>4 (1–9)</td>
</tr>
<tr>
<td>Patients with prior radiation therapy</td>
<td>11</td>
</tr>
<tr>
<td>Patients with prior VEGF blocking therapy</td>
<td>6</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
</tr>
<tr>
<td>Embryonal ($n = 9$)</td>
<td></td>
</tr>
<tr>
<td>Hepatoblastoma</td>
<td>6</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>2</td>
</tr>
<tr>
<td>Wilms tumor</td>
<td>1</td>
</tr>
<tr>
<td>Sarcoma ($n = 7$)</td>
<td></td>
</tr>
<tr>
<td>Ewing sarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Alveolar rhabdomyosarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Synovial sarcoma</td>
<td>1</td>
</tr>
<tr>
<td>Other soft tissue sarcoma (including clear cell, epithelioid, and leiomyosarcoma)</td>
<td>4</td>
</tr>
<tr>
<td>Carcinoma ($n = 3$)</td>
<td></td>
</tr>
<tr>
<td>Adrenocortical</td>
<td>1</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Small cell/large cell carcinoma</td>
<td>1</td>
</tr>
<tr>
<td>Brain tumor ($n = 2$)</td>
<td></td>
</tr>
<tr>
<td>Ependymoma</td>
<td>1</td>
</tr>
<tr>
<td>Pilocytic astrocytoma</td>
<td>1</td>
</tr>
</tbody>
</table>

### Table 2. Cycle 1 and 2 DLTs

<table>
<thead>
<tr>
<th>Dose</th>
<th>Entered</th>
<th>Evaluable</th>
<th>DLT</th>
<th>Description of DLT (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0 mg/kg</td>
<td>7</td>
<td>6</td>
<td>1</td>
<td>Hemorrhage, suspected tumor bleed (1)</td>
</tr>
<tr>
<td>2.5 mg/kg</td>
<td>7</td>
<td>6</td>
<td>0</td>
<td>Tumor/soft tissue necrosis (1), tumor pain (1)</td>
</tr>
<tr>
<td>3.0 mg/kg</td>
<td>7</td>
<td>6</td>
<td>2</td>
<td>Tumor/soft tissue necrosis (1), tumor pain (1)</td>
</tr>
</tbody>
</table>
sustained across the entire dosing interval (Fig. 1). For example, at the MTD, the median (range) free and bound aflibercept serum concentrations on day 8 were 4.96 (3.33–6.02) and 2.39 (2.06–2.69) mg/mL, respectively (ratio free/bound: 2.10), whereas on day 15, they were 1.45 (0.99–2.01) and 3.35 (2.10–3.97) mg/mL (ratio: 0.44). Nonetheless, detectable free aflibercept at the end of the dosing cycle suggests that all available VEGF was bound and neutralized.

Sixteen subjects had samples submitted for measurement of anti-aflibercept antibody. The subject who received 16 doses of aflibercept was the only one to develop detectable drug-specific antibody but without clinical signs of hypersensitivity. In the adult phase I study, no anti-aflibercept antibody was detected (7). The incidence of antibody development for patients on longer term therapy is currently unknown.

Samples for blood biomarker (VEGF, sVEGFR-2, sVEGFR-1, and PlGF) analysis were available for a minority of patients (n = 9; paired n = 6). Mean baseline VEGF level was 112 pg/mL [median (range), 114 pg/mL (48–153)] and mean baseline PlGF level was 14.9 pg/mL [median (range), 13.9 pg/mL (9.4–30.3)]. In aggregate, a rapid and significant decrease in VEGF (P < 0.05) and increase in PlGF (P < 0.05) from baseline was observed in response aflibercept by day 2, which was maintained through day 15 (Fig. 2). The more than 10-fold increase in PlGF levels to 837 pg/mL [median (range), 938 pg/mL (472–987)] by day 15 suggests that aflibercept treatment induced the expression of PlGF, as described in previous reports for aflibercept and other anti-VEGF agents (15, 16). Because of small numbers, these PD parameters could not be correlated with dose level or response. In contrast to recent studies of the antiangiogenic multi-tyrosine kinase inhibitors, no modulation of sVEGFR-2 was noted, nor was there a change in sVEGFR-1. Samples for total and subsets of circulating endothelial cells were submitted for 10 patients, but only 4 subjects had 3 serial time points for analysis. In this small data set, no reliable changes could be observed with therapy (data not shown).

**Table 3.** Non-DLTs with possible, probable, or definite relationship to protocol therapy

<table>
<thead>
<tr>
<th>Toxicity type</th>
<th>Course 1 (18-patient courses)</th>
<th>Courses 2–8 (19-patient courses)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade I</td>
<td>Grade II</td>
</tr>
<tr>
<td>Hematologic toxicities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Leukopenia (WBC)</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Platelets</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Non-hematologic toxicitiesa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Fatigue</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Voice changes</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Hypoalbuminemia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>PTT</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Abbreviation: WBC, white blood cells.
aNonhematologic toxicities that were observed in more than 10% of patients.
Response evaluation
The median number of aflibercept 4-week courses was 1 (range, 1–8). There were no objective responses. Three patients had a best response of stable disease with diagnoses of hepatocellular carcinoma (13.4 weeks), clear cell sarcoma (23.6 weeks), and hepatoblastoma (30.8 weeks). None of these 3 had received prior anti-VEGF therapy.

Discussion
Twenty-one children were treated at aflibercept doses of 2.0, 2.5, and 3.0 mg/kg, with an MTD of 2.5 mg/kg. This pediatric MTD is lower than the adult recommended dose of 4.0 mg/kg and is in contrast to adult phase I studies, wherein no DLTs were found up to 6 mg/kg (7, 9). In the 3 patients who experienced a DLT, the toxicities observed may well be from the effects of VEGF blockade on tumor vasculature, with suspected tumor hemorrhage, tumor pain, and tumor necrosis (rupture). Increased risk of bleeding, including serious intratumoral hemorrhage, was appreciated early in the development of VEGF-targeted therapy including the neutralizing antibody bevacizumab (17), and while infrequent, the association of this toxicity with VEGF inhibitors is supported by a recent meta-analysis (18). While the precise mechanism remains unknown, it is understood that the VEGF pathway plays an important role in maintaining endothelial–vascular mural cell homeostasis, both under normal physiologic and pathologic conditions. Potent VEGF blockade with aflibercept was shown to induce concurrent tumor endothelial and perivascular cell apoptosis, associated with rapid and dramatic reductions in vessel number, branching and perfusion in an orthotopic model of established tumors from the Ewing sarcoma family (4). Such changes may lead to endothelial dysfunction, a loss of vascular integrity, and subsequent vascular collapse or bleeding (19). In the setting of progressive disease, it would be difficult to definitively conclude that these toxicities were due to these “on target” effects of aflibercept, but the hypothesis is intriguing.

Although the tumor types were various (adrenal cortical carcinoma, epithelioid sarcoma, synovial sarcoma), it has also been found that certain tumors histologies have increased propensity for necrosis and associated hemorrhage after treatment with VEGF blockade (e.g., non–small cell lung cancer of squamous cell histology with bevacizumab; ref. 20). Notably, the index case of subcutaneous tumor necrosis, hemorrhage, and rupture during adult phase I testing of bevacizumab also occurred in a patient with epithelioid sarcoma, similar to the patient in our trial (17). Whether pediatric tumors in general, or even limited histologies, have an increased susceptibility to VEGF.

Table 4. Mean PK of free aflibercept

<table>
<thead>
<tr>
<th>Subject</th>
<th>Dose, mg/kg</th>
<th>t1/2, d</th>
<th>Cmax, µg/mL</th>
<th>AUC0–∞, µg/mL d</th>
<th>Cl, mL/d/kg</th>
<th>Vz, mL/kg</th>
<th>Vss, mL/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.0</td>
<td>4.79</td>
<td>25.8</td>
<td>145</td>
<td>13.8</td>
<td>98.6</td>
<td>79.3</td>
</tr>
<tr>
<td>7</td>
<td>2.0</td>
<td>5.67</td>
<td>25.0</td>
<td>164</td>
<td>12.2</td>
<td>99.9</td>
<td>92.1</td>
</tr>
<tr>
<td>18</td>
<td>2.5</td>
<td>5.20</td>
<td>12.2</td>
<td>109</td>
<td>23.0</td>
<td>172.4</td>
<td>159.2</td>
</tr>
<tr>
<td>20</td>
<td>2.5</td>
<td>3.55</td>
<td>24.1</td>
<td>116</td>
<td>21.5</td>
<td>109.8</td>
<td>93.0</td>
</tr>
<tr>
<td>9</td>
<td>3.0</td>
<td>3.93</td>
<td>56.9</td>
<td>168</td>
<td>17.9</td>
<td>101.2</td>
<td>82.2</td>
</tr>
<tr>
<td>10</td>
<td>3.0</td>
<td>4.89</td>
<td>58.7</td>
<td>187</td>
<td>16.0</td>
<td>112.9</td>
<td>88.2</td>
</tr>
<tr>
<td>12</td>
<td>3.0</td>
<td>2.64</td>
<td>44.5</td>
<td>119</td>
<td>25.2</td>
<td>95.9</td>
<td>85.7</td>
</tr>
<tr>
<td>14</td>
<td>3.0</td>
<td>4.84</td>
<td>32.9</td>
<td>169</td>
<td>17.7</td>
<td>123.6</td>
<td>126.1</td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td>4.46</td>
<td></td>
<td></td>
<td>18.4</td>
<td>114</td>
<td>101</td>
</tr>
<tr>
<td>SD</td>
<td></td>
<td>1.00</td>
<td></td>
<td></td>
<td>4.5</td>
<td>25</td>
<td>28</td>
</tr>
<tr>
<td>% CV</td>
<td></td>
<td>23</td>
<td></td>
<td></td>
<td>25</td>
<td>22</td>
<td>28</td>
</tr>
</tbody>
</table>

Abbreviations: Cl, clearance; CV, coefficient of variance; t1/2, half-life; Vz, volume of distribution at terminal phase.
inhibition remains to be determined. Asymptomatic pneumothorax was previously seen in pediatric sarcoma patients with pulmonary metastases receiving cediranib, a potent VEGF receptor tyrosine kinase inhibitor, but these were manageable and were not considered dose-limiting. The pneumothoraces in this setting were appreciated only in the presence of tumor response and were postulated to be due to either necrosis of a pleural-based or peripherally located nodule, bronchopleural fistula, or alveolar rupture (12). In the cediranib pediatric phase I trial, and that of bevacizumab (13), the MTD for children was approximately equivalent to the adult recommended dosing.

Another potential contributing factor to the tumor-associated DLT seen in this study may relate to tumor size: 2 tumors were >10 cm in diameter, and the third >6 cm in diameter. Prior exposure to a VEGF inhibitor and/or radiation to the area of tumor recurrence may have also been predisposing factors. Bulky disease, previous anti-VEGF therapy, and prior tumor radiation were not exclusionary and may have compromised our ability to escalate to higher doses.

The presence of DLTs at lower doses of aflibercept than those given in adult clinical trials does not appear to be due to differences in PK. In our pediatric study, we found mean half-life, clearance, and volume of distribution at steady state (\(V_{ss}\)) values of free aflibercept of 4.5 days, 18.4 mL/kg/d, and 101 mL/kg, respectively, which are similar to values reported in adults (7, 9). Because of the limited dose range, no meaningful difference in C\(_{\text{max}}\) and AUC could be detected between doses of 2.0 g/mL and 2.5 mg/kg, which was comparable with the adult experience at 2.0 mg/kg, but only a third of the exposure seen at the recommended adult dose of 4.0 mg/kg. It is therefore possible that our MTD is too low to achieve effective concentrations of aflibercept; however, in the presence of severe dose-limiting side effects that might be related to the mechanism of the agent, and may actually be an indication of drug activity, further dose-escalation was not felt to be justified.

Preclinical studies have shown that the biologic effects of aflibercept correlate with free aflibercept levels in excess of bound and that the level of bound aflibercept is associated with VEGF production due to the stability of VEGF:afibercept complex (21). At the MTD of 2.5 mg/kg, free in excess of complexed aflibercept was sustained for 8 days (ratio: 2.10), but free aflibercept decreased below bound aflibercept by day 15 (ratio: 0.44). Free in excess of bound aflibercept was also not sustainable at 3 mg/kg. In contrast, in adults, doses of 2 mg/kg and greater were adequate to maintain free in excess of complexed aflibercept (7). However, levels of bound aflibercept in children (3.4 μg/mL) were overall higher than levels observed in adults (1.6 μg/mL; see ref. 7). While it is understood that children with cancer have higher VEGF levels than normal age-matched controls and that circulating VEGF levels decline with tumor remission (22, 23), it is unknown whether children without cancer have higher circulating endogenous VEGF when compared with healthy adults, or whether pediatric tumor VEGF production, or simply bulk disease, make a greater contribution to systemic levels in patients with cancer. Nonetheless, in our study, the mean baseline plasma VEGF level was 112 pg/mL (\(n = 9\); median (range): 114 pg/mL (48–153)] which is more than twice that noted in a cohort of adults with metastatic renal carcinoma of 45.8 [\(n = 69\); median (range): 18.6 pg/mL (0.3–553); ref. 24]. Bound VEGF concentrations continued to increase in the few children who remained on study for up to 5 courses, suggesting an ongoing compensatory increase in VEGF production. Whether sustained aflibercept excess throughout treatment is required for optimal, durable biologic effect in human cancer therapy, or whether short-term excess, but persistent measurable levels of free aflibercept will be sufficient, remains to be determined in adult clinical trials.

As yet, there are no accepted or proven biomarkers of angiogenic inhibition. However, rapid changes in the exploratory markers of activity described here are similar to findings in adults, where changes in VEGF and PIGF

<table>
<thead>
<tr>
<th>Dose, mg/kg</th>
<th>Cycle</th>
<th>Free aflibercept concentrations, ng/mL</th>
<th>Bound aflibercept concentrations, ng/mL</th>
<th>Free/bound</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Free</td>
<td>Bound</td>
<td>Free/bound</td>
<td></td>
</tr>
<tr>
<td>2.0</td>
<td>Cycle 1, d 8 ((n = 3))</td>
<td>6.86 (6.16–7.56)</td>
<td>2.50 (1.76–3.96)</td>
<td>3.87</td>
</tr>
<tr>
<td></td>
<td>Cycle 2, pretreatment ((n = 5))</td>
<td>1.50 (0.12–3.43)</td>
<td>3.61 (2.05–6.22)</td>
<td>0.52</td>
</tr>
<tr>
<td></td>
<td>Cycle 5, pretreatment ((n = 3))</td>
<td>4.20 (1.81–8.01)</td>
<td>8.16 (4.47–13.20)</td>
<td>0.43</td>
</tr>
<tr>
<td>2.5</td>
<td>Cycle 1, d 8 ((n = 5))</td>
<td>4.96 (3.33–6.02)</td>
<td>2.39 (2.06–2.69)</td>
<td>2.10</td>
</tr>
<tr>
<td></td>
<td>Cycle 2, pretreatment ((n = 5))</td>
<td>1.45 (0.99–2.01)</td>
<td>3.55</td>
<td>0.44</td>
</tr>
<tr>
<td></td>
<td>Cycle 5, pretreatment ((n = 1))</td>
<td>0.49</td>
<td>4.34</td>
<td>0.11</td>
</tr>
<tr>
<td>3.0</td>
<td>Cycle 1, d 8 ((n = 4))</td>
<td>7.46 (4.59–9.94)</td>
<td>1.96 (1.78–2.21)</td>
<td>3.88</td>
</tr>
<tr>
<td></td>
<td>Cycle 2, pretreatment ((n = 6))</td>
<td>2.20 (0.81–4.15)</td>
<td>3.27 (2.79–3.84)</td>
<td>0.71</td>
</tr>
<tr>
<td></td>
<td>Cycle 5, pretreatment ((n = 0))</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Values represent mean concentrations with range in parentheses. At the 2 mg/kg dose, one patient had bound measurements at each time point, but free measurements only for the cycle 5, pretreatment time point.
concentrations have been correlated with decreased vascular permeability on dynamic imaging (15). The incidence of hypertension in children in this trial also appears to be similar to that at the adult recommended phase II dose, supporting the biologic activity of aflibercept over the dose range (2.0–3.0 mg/kg) studied. Identifying biomarkers which can indicate adequate exposure and predict which patients might benefit from anti-VEGF therapy, especially given their potential for rare but serious side effects, remains crucial. Measurement of circulating endothelial and progenitor cells is complicated, costly, and has not yielded consistent results. Future considerations for trials of antiangiogenic agents in pediatrics should consider incorporating studies of VEGF single-nucleotide polymorphisms, dynamic imaging endpoints, and an assessment of a broader base of serum markers including the CXCL12 (SDF-1)/CXCR4 axis (25).

In summary, the recommended pediatric MTD for aflibercept is 2.5 mg/kg/dose every 14 days, which is lower than the adult recommended dose of 4.0 mg/kg. The occurrence of tumor-associated toxicity in the setting of massive disease burden is a strong argument in favor of biologic activity at the dose range tested. While there were no objective responses to aflibercept, 3 patients did have stable disease for >12 weeks, suggesting that some pediatric nonbulky tumors may benefit from potent VEGF inhibition therapy.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References

Authors’ Contributions
Conception and design: J. Glade Bender, S.M. Blaney, S. Borinstein, A. Chen, P.C. Adamson, J.R. Park
Development of methodology: J. Glade Bender, S. Borinstein, A. Chen, P.C. Adamson, J.R. Park
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Glade Bender, S. Baruchel, A.M. Ingle, B. Weigel, J.R. Park
Analysis and interpretation of data (e.g., statistical analysis, bioinformatics, computational analysis): J. Glade Bender, S. Borinstein, J.M. Reid, S. Baruchel, C. Ahern, A.M. Ingle, D.J. Yamashiro, J.R. Park
Writing, review, and/or revision of the manuscript: J. Glade Bender, S.M. Blaney, J.M. Reid, S. Baruchel, C. Ahern, A.M. Ingle, D.J. Yamashiro, A. Chen, B. Weigel, P.C. Adamson, J.R. Park
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Glade Bender, A.M. Ingle
Study supervision: J. Glade Bender, S.M. Blaney, A.M. Ingle, A. Chen, B. Weigel, J.R. Park
Reference laboratory: S. Baruchel

Acknowledgments
The authors thank Elizabeth O’Connor, Biljana Georgievska, and Nicole Stewart from the COG Phase 1/Pilot Consortium Operations Center for outstanding data management and administrative support throughout the development and conduct of this trial, and Bing Wu for her diligence in carrying out the biomarker analysis.

Grant Support
The study was supported by Alex’s Lemonade Stand Foundation, tay-bands, Sanofi-Aventis, and the Phase I/Pilot Consortium Grant U01 CA97452 of the Children’s Oncology Group from the NCI, NIH, Bethesda, Maryland.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 9, 2012; revised June 5, 2012; accepted June 20, 2012; published OnlineFirst July 12, 2012.


